Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  Velpatasvir

Velpatasvir

Basic information Safety Supplier Related

Velpatasvir Basic information

Product Name:
Velpatasvir
Synonyms:
  • Velpatasvir
  • GS 5816
  • velpatasvir(GS-5816)
  • methyl ((2s)-1-((2s,5s)-2-(9-(2-((2s,4s)-1-((2r)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-1,11-dihydroisochromeno(4',3':6,7)naphtho(1,2-d)imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
  • Velpatasvir API
  • Unifiram (DM-232)
  • GS 5816;GS-5816
  • CS-2204
CAS:
1377049-84-7
MF:
C49H54N8O8
MW:
883
EINECS:
1592732-453-0
Product Categories:
  • 1377049-84-7
Mol File:
1377049-84-7.mol
More
Less

Velpatasvir Chemical Properties

Melting point:
>170oC (dec.)
Density 
1.314±0.06 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
Soluble in DMSO (>25 mg/ml)
pka
10.75±0.46(Predicted)
form 
solid
color 
Pale yellow
Stability:
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKey
FHCUMDQMBHQXKK-CDIODLITSA-N
SMILES
C(OC)(=O)N[C@H](C1=CC=CC=C1)C(N1C[C@@H](COC)C[C@H]1C1NC(C2=CC=C3C4C(OCC3=C2)=CC2=C3C(=CC=C2C=4)N=C([C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(OC)=O)C(C)C)N3)=CN=1)=O
More
Less

Velpatasvir Usage And Synthesis

Description

Velpatasvir (1377049-84-7) is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa? and Vosevi?, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV.? It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2

Uses

Velpatasvir is a NS5A inhibitor in patients with hepatitis C (HCV) infection.

Definition

ChEBI: Velpatasvir is a complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. It has a role as an antiviral drug and a hepatitis C virus nonstructural protein 5A inhibitor. It is an organic heteropentacyclic compound, a N-acylpyrrolidine, a L-valine derivative, a carbamate ester, a member of imidazoles, a ring assembly and an ether.

brand name

Epclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)

in vivo

Velpatasvir (10 mg/kg/d, p.o.) alone or in combination with Sofosbuvir (HY-15005) (20 mg/kg/d) inhibits liver fibrosis in the CCl4-induced non-HCV rat model[3].

Animal Model:CCl4-induced non-HCV rat model[3]
Dosage:10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d)
Administration:p.o.
Result:Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues.
Inhibited hepatic stellate cells (HSCs).

References

[1] JOHN O. LINK . Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®[J]. Bioorganic & Medicinal Chemistry Letters, 2019, 29 16: Pages 2415-2427. DOI:10.1016/j.bmcl.2019.04.027
[2] ONAT KADIOGLU . Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning[J]. Computers in biology and medicine, 2021, 133: Article 104359. DOI:10.1016/j.compbiomed.2021.104359

VelpatasvirSupplier

Hangzhou Cheminspire Technology Co., Ltd. Gold
Tel
0571-89081561; 10006559855
Email
info@cheminspire.com
INTERCHEMIE NANJING PHARMATECH CO., LTD Gold
Tel
13656237714 13656237714;
Email
xiaokunfu@kyyykj.com
Shanghai Neff Biotechnology Co., LTD Gold
Tel
14782051321
Email
market@lifebiology.cn
Shanghai jing Hao pharmaceutical technology co., LTD Gold
Tel
021-68900963 15618693615
Email
sales@jinghaopharma.com
NANJING ZENJI PHARMACEUTICALS Gold
Tel
025-58231105-8151
Email
marketing@zenjipharma.com